Be the first to review this item
Encephabol (Pyritinolum, Pyritinol) - neuroprotective drugs. Pyritinol increases pathologically decreased metabolism in the brain by increasing the capture and utilization of glucose metabolism raises the nucleic acids and the release of acetylcholine in the synapses of the nerve cells, improve cholinergic transmission between nerve tissue cells. It helps stabilize the cell membranes of nerve cells and their structure by inhibiting the function of lysosome enzymes, preventing the formation of these free radicals.
Pyritinol improve blood rheology, plasticity of the erythrocytes increases by increasing their ATP content in the membrane, which leads to lower blood viscosity and improving blood flow. Pyritinol, improving blood circulation in the ischemic areas of the brain, increases their oxygen supply; improves glucose metabolism. As a result, improved memory performance and to restore the broken metabolism in nervous tissue that contributes to the full functioning of its cells.
Pyritinol rapidly absorbed after oral administration. Bioavailability is an average of 85% (76-93%). Maximum plasma concentration is reached 30-60 minutes after ingestion of 100 mg Pyritinol. The half-life of about 2.5 hours.
Pyritinol quickly metabolized. 20-40% of the material is reversibly bound to plasma proteins. Identified as major metabolites following substances: 2-methyl-3-hydroxy-4-hydroxymethyl-5-metilmerkaptometilpiridin and 2-methyl-3-hydroxy-4-hydroxymethyl-5-metilsulfinilmetilpiridin. Conjugated metabolites are excreted primarily through the kidneys. The total urinary excretion within 24 hours of 72,4-74,2%. The largest part of the administered dose is excreted in the first 4 hours after ingestion. C fecal output only 5% of the dose.
Repeated oral administration of cumulation is not observed. Toxic concentrations do not develop even with impaired renal function.
It penetrates the blood-brain barrier, metabolites accumulate predominantly in the gray matter of the brain.
Pyritinol crosses the placental barrier. The studies did not reveal any teratogenic or embryotoxic activity.
In patients with rheumatoid arthritis and other chronic diseases of the joints have the sensitivity to compounds which include SH-group, including to Pyritinol. These patients have increased risk of hypersensitivity reactions, immunopathological reactions and disorders of taste sensitivity and liver function. In carrying out the treatment of these patients requires systematic monitoring of common blood tests, urine, hepatic function, immunological parameters.
Hypersensitivity reactions to the drug may occur in patients with hypersensitivity to D-penicillamine, as the latter is similar to the chemical structure Pyritinol (thiol groups).
When using encephabol on the testimony, as a rule, there are no restrictions on the types of activities that require attention, fast psychomotor reactions. However, given the likelihood of an individual patient to the drug response of individual differences, at the beginning of treatment and at higher dose should be considered the possibility of breaking the speed of psychomotor reactions.
When receiving encephabol in accordance with the indications and at the recommended doses, side effects should be expected.
Sometimes - hypersensitivity reactions of varying severity: skin rash or mucous membranes, itching, nausea, vomiting, diarrhea, fever, insomnia.
Rarely - increased irritability, loss of appetite, headache, dizziness, fatigue, change in taste, abnormal liver function (increased levels of transaminases, cholestasis).
In an application Encephabol may potentiate the side effects of penicillamine, sulfasalazine and gold products. Clinically significant interaction encephabol with other drugs has not been established.
The mode set individually depending on the severity of the condition and the effectiveness of therapy.
Taking the drug should be during or after a meal. When sleep disturbances last daily dose should not be taken in the evening or at night. The duration of treatment depends on the clinical picture of the disease.
For adults, the mean dose of 600 mg / day (2 tab. 3 times / day).
Newborns Encephabol administered 3 days after birth to 20 mg per day for a month, the drug should be given in the morning.
Children aged 2 months dose increased by 20 mg weekly until until it reaches a daily dose of 100 mg.
Children aged 1 year to 7 years administered in a daily dose of 50 mg to 300 mg depending on the evidence.
For children older than 7 years of daily dose is from 50 mg to 600 mg (2.1 Tab. 1-3 times / day).
In acute conditions, and the appointment of the drug in high doses, a marked therapeutic effect is achieved after a few hours or days.
In chronic diseases (including consequences of traumatic brain injury or dementia) a significant therapeutic success is achieved after 2-4 weeks of treatment. Optimal and steady effect is usually 6-12 weeks. The duration of treatment for chronic diseases should be at least 8 weeks.
In infants at high risk of perinatal pathology of the average duration of treatment is 6 months, while 3 months should check for indications for further treatment.
Important notice- the outer box design may vary before prior notice!
Someone from the Oman - just purchased the goods:
Stamakort intensive course 180 capsules